NDAINHALATIONSPRAY
Approved
Sep 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
3/8 — Basic
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SPIRIVA RESPIMAT is a tiotropium bromide inhalation spray approved by the FDA on September 15, 2015, as a small molecule therapeutic delivered via the RESPIMAT inhaler device. It is indicated for maintenance treatment of chronic obstructive pulmonary disease (COPD) and works as a long-acting anticholinergic bronchodilator. The product represents an innovative delivery formulation of tiotropium, offering improved ease of use compared to powder inhalers, positioning it as a preferred maintenance therapy option in COPD management.
$0.9BPart D
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Characteristics of Pts Initiating Spiriva Respimat in Asthma
Started Mar 2019
116,133 enrolled
Asthma
Specific Use-Result of Spiriva Respimat® in Asthmatics
Started Jul 2017
193 enrolled
Asthma
Specific Use-result Surveillance of Spiriva Respimat in Asthmatics
Started Jun 2015
359 enrolled
Asthma
Observational Non-Interventional Study With Spiriva Respimat in COPD Patients
Started Jun 2008
1,280 enrolled
Pulmonary Disease, Chronic Obstructive
Why This Matters for Your Career
Worked on SPIRIVA RESPIMAT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.